MannKind vs OPKO Health
MNKD and OPK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MNKD and OPK compare
MannKind and OPKO Health are about the same size, with market caps of $1.3B and $1.3B.
MannKind grew revenue faster over the last twelve months (31.7% versus −8.3% for OPKO Health).
MannKind keeps more of each dollar of sales as profit, with a net margin of −18.1% compared with −29.5% at OPKO Health.
OPKO Health scores higher on the StockData Score (8 against 6 for MannKind), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MNKD | OPK |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $1.3B |
| Share price | $4.13 | $1.68 |
| Change, 1 year | −21.3% | 27.3% |
| Change, 5 years | −13.1% | −61.4% |
| Beta (5Y) | 1.07 | 0.92 |
| Employees | 241 | 2,275 |
| StockData Score | ||
| Total score | 6 | 8 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 2 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.2× | 2.5× (better) |
| P/B | – | 1.1× |
| EV/EBITDA | 87.0× | – |
| FCF yield | −5.9% (better) | −10.8% |
| Fair value | $1.11 | $2.10 |
| Margin of safety | −273% | 20.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 31.7% (better) | −8.3% |
| Revenue growth, 5Y average | 39.9% (better) | −15.8% |
| Net income growth (TTM) | −356% | – |
| EPS growth (TTM) | −330% | – |
| Profitability | ||
| Gross margin | 88.6% (better) | 56.6% |
| Operating margin | −2.9% (better) | −17.5% |
| Net margin | −18.1% (better) | −29.5% |
| FCF margin | −19.0% (better) | −27.0% |
| Return on equity | – | −12.2% |
| Return on invested capital | – | −8.5% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −0.3× | – |
| Current ratio | 2.22 | 4.97 (better) |
| Altman Z-score | −4.52 | −0.28 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 3.3% |
| Shareholder yield | 0.00% | 3.3% (better) |
| Ownership | ||
| Held by institutions | 56.7% | 27.2% |
| Held by insiders | 2.5% | 43.6% |
| Insider net buying, 12 months | −$2.9M | −$13.2K (better) |
| Short interest, % of float | 8.4% | 7.8% |
Go deeper
- MNKD stock overview
- MNKD income statement
- MNKD valuation and score
- OPK stock overview
- OPK income statement
- OPK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.